THE GLP-1
REVOLUTION
30 YEARS FROM NOW
This is DEEP RESEARCH on the economic and societal repercussions of broad adoption of Glucagon-like peptide-1 (GLP-1) across the USA and world.
Below this macro study data you will find sources, the ability to download a free copy of the study, and each of our YouTube episodes in our GLP1 Revolution Series – exclusivly from Garage Talk.
🧠
NEUROMODULATION 2056
Forecasting GLP-1 Receptor Agonists on Human Behavior & Society
30-Year Macroeconomic & Societal Model
The Reprogramming of Human Desire
By blunting phasic dopamine spikes in the mesolimbic reward system, widespread GLP-1 adoption fundamentally transforms addiction, violent crime, and global vice economies. Explore the projected timeline below.
Adjust slider to observe population-level adoption effects.
2026 (Emergent)
2036 (Expansion)
2046 (Generic Era)
2056 (Ubiquitous)
US Adoption Level
42%
Universal prophylactic deployment
DUI Deaths Saved/Yr
10,700
-80% reduction from 2021 baseline
Opioid Overdose Reduction
-65%
Sustained craving blunting
Annual Health Dividend
$425B
Reduced ER, trauma & chronic costs
1. Neurobiological Mechanisms: Reprogramming Reward
How GLP-1 receptor agonists alter synaptic plasticity in the Nucleus Accumbens (NAc) and Ventral Tegmental Area (VTA) to dampen cue salience.
Central Nervous System Target Architecture
GLP-1 is synthesized centrally by preproglucagon neurons in the Nucleus of the Solitary Tract (NTS) in the brainstem. These project to the VTA and Nucleus Accumbens—the epicenter of the mesolimbic dopamine pathway.
By modulating AMPA/kainate glutamatergic inputs and increasing presynaptic glutamate release, GLP-1 RAs lower the peak height of phasic dopamine spikes during reward anticipation.
Pharmacodynamic Risk: Anhedonia
Selective G-protein cAMP signaling without β-arrestin desensitization risks persistent dopaminergic over-suppression—inducing emotional flattening, sexual apathy, and clinical anhedonia in vulnerable users.
Dopamine Spike Intensity by Stimulus Category
Normalized scale (0-100). Data modeled from preclinical and clinical NAc dopamine signal studies.
2. The Spectrum of Pleasure: Clinical & Observational Data
Examining empirical evidence across substance use disorders, risk-taking behaviors, and human intimacy.
Alcohol Use Disorder (AUD)
Severing the Compulsive Loop
Clinical trial data (JAMA Psychiatry 2025) indicates semaglutide truncates binge sessions without requiring complete abstinence. Patients retain the cognitive ability to stop after one drink as the anticipatory compulsion for the second or third drink is neutralized.
Drinks Per Binge Session
-54% Reduction
Opioid Use Disorder (OUD)
Overdose Protection Shield
A 2024 emulation target trial of 33,000+ patients demonstrated semaglutide users experienced a 42% to 68% lower risk of opioid overdose. Unlike methadone, GLP-1 RAs carry zero abuse potential and do not induce withdrawal.
Hazard Ratio Overdose Lowering
0.32 - 0.58 HR
4. Financial Impact Forecast: Vice Economy vs Health Dividend
The macroeconomic paradox: Trillions in public health savings paired with structural contractions in compulsion-driven industries.
Healthcare Savings vs. Vice Industry Contraction ($B/Year)
The Public Health Peace Dividend
US substance abuse currently drains $532B annually. Universal GLP-1 adoption deflates ER poisoning visits, ICU trauma stays, and chronic diabetes/metabolic costs, creating massive municipal budget relief.
The "Vice Economy" Liquidation
Alcohol, gaming, and fast fashion rely on Pareto economics (80% revenue from top 20% compulsive users). As chemical dependency is severed, volume markets collapse, forcing a shift to low-volume, high-margin "tasting" models.
| Economic Sector | Current Model | 2056 Macro Outlook |
|---|---|---|
| Alcohol & Spirits | High volume heavy users | Mass market collapse; craft tasting only |
| Casinos & Gaming | Dopamine loop slots | Pivot to non-gaming luxury hospitality |
| Healthcare Systems | Reactive chronic care | Trillion-dollar cumulative dividend |
Societal Trade-Off Framework
The "Safe But Muted" Human Experience
While 2056 statistics demonstrate unprecedented declines in violence, overdoses, and vehicular carnage, the systemic suppression of the mesocorticolimbic pathway raises profound existential questions.
✓ What We Gain
Eradication of destructive addictions, safer highways, dramatic drops in domestic assault, extended lifespan, and reduced healthcare burdens.
⚠️ What We Risk
Population-level affective flattening, reduced peak euphoria, diminished natural libido, and a loss of spontaneous artistic or passionate drive.
SOURCES
- GLP-1s are just the beginning | McKinsey & Company, https://www.mckinsey.com/featured-insights/themes/glp-1s-are-just-the-beginning
- A new way of thinking about metabolic health and obesity – McKinsey, https://www.mckinsey.com/mhi/our-insights/a-new-way-of-thinking-about-metabolic-health
- Why the anti-obesity drug market could grow to $100 billion by 2030, https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market
- GLP-1 Market Expected to More Than Double to $190B by 2035, https://www.morganstanley.com/insights/articles/glp1-weight-loss-market-may-double-190-billion-2035
- How Supply and Demand for Weight Loss Drugs is Playing Out in, https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
- FDA approves Lilly obesity pill, triggering battle with Novo Nordisk, https://www.biopharmadive.com/news/fda-approves-lilly-obesity-pill-orforglipron-foundayo-novo/816359/
- Next Order Effects of Increasing GLP-1 Use | Morgan Stanley, https://www.morganstanley.com/im/en-us/institutional-investor/insights/articles/effects-of-increasing-glp-1-use.html
- Oral Obesity Drugs Market Size, GLP-1 Pills and Forecast 2026-2035, https://www.datamintelligence.com/research-report/oral-obesity-drugs-market
- Novo Nordisk launches first GLP-1 pill for obesity, but Lilly may, https://www.drugdiscoverytrends.com/novo-nordisk-launches-first-glp-1-pill-for-obesity-but-lilly-may-dominate-the-oral-market-eventually/
- Could orforglipron reshape the GLP-1 market?, https://www.managedhealthcareexecutive.com/view/could-orforglipron-reshape-the-glp-1-market-
- Novo Nordisk Dominates Oral Obesity Drug Market, Pressuring Eli, https://finance.biggo.com/news/d967c0c8-504a-4248-876d-fe696d599f58
- What to Know About the BALANCE Model for GLP-1s in Medicare, https://www.proactivefqhc.org/what_to_know_about_the_balance_model_for_glp_1s_in_medicare_and_medicaid
- The BALANCE Model and a New Wave of CMS Drug Pricing Models, https://www.mintz.com/insights-center/viewpoints/2146/2026-01-05-balance-model-and-new-wave-cms-drug-pricing-models
- Bridging the gap: The future of GLP-1 coverage in Part D, https://avalerehealth.com/thought-leadership/bridging-the-gap-the-future-of-glp-1-coverage-in-part-d/
- What to Know About the BALANCE Model for GLP-1s in Medicare, https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/
- Fiscal Impact of Expanded Medicare Coverage for GLP-1 Receptor, https://pmc.ncbi.nlm.nih.gov/articles/PMC12032556/
- GLP-1 Prescriptions for Weight Loss by Differences in Insurance, https://pmc.ncbi.nlm.nih.gov/articles/PMC13309865/
- Weighing Pros, Cons of GLP-1 Drug Coverage for Employers, https://www.sentinelgroup.com/resource-center/2025/pros-cons-glp-1-receptor-agonist-for-employers
- The Employer’s GLP-1 Dilemma: Balancing Quality Care and Cost, https://www.rxbenefits.com/blogs/the-employers-glp-1-dilemma-balancing-quality-care-and-cost-control/
- GLP-1 medications and employer health care costs | Higginbotham, https://www.higginbotham.com/blog/glp1-employer-healthcare-costs/
- What are GLP-1 medications? – McKinsey, https://www.mckinsey.com/featured-insights/mckinsey-explainers/what-are-glp-1-medications
- How are GLP-1s Affecting the Food Industry? – Ingredient Exchange, https://ingexchange.com/blog/glp1s-effect-on-food-industry/
- GLP-1 Growth Strategy Examples from Danone, Conagra & Nestlé, https://itoaction.com/glp-1-growth-strategy-examples/
- GLP-1 Medications Shift US Retail Foot Traffic and Sales – CRE Daily, https://www.credaily.com/briefs/glp-1-medications-shift-us-retail-foot-traffic-and-sales/
- The Impact of GLP-1 Drugs on the Agri-Food System – Product Center, https://www.canr.msu.edu/resources/the-impact-of-glp-1-drugs-on-the-agri-food-system
- GLP-1 Medication Effect on Food Industry | GLP-1 Friendly Ingredients, https://www.americaninternationalfoods.com/2025/10/20/glp-1-medication-effect/
- GLP-1 drugs put $73B in global food value at risk, report finds, https://www.fooddive.com/news/glp-1-drugs-snacking-pepsico-reeses-kellogg-cheetos-doritos/830551/
- GLP-1 Rewrites CPG Strategy – Foodgraph, https://www.foodgraph.com/blog/glp-1-rewrites-cpg-strategy
- Will Big Food outsmart GLP-1s? | British Columbia Medical Journal, https://bcmj.org/editorials/will-big-food-outsmart-glp-1s
- GLP-1 Medication Usage is Impacting the U.S. Apparel Industry, https://www.circana.com/post/glp-1-medications-are-reshaping-the-us-apparel-industry-according-to-circana
- How GLP-1 Meds are Reshaping the US Apparel Market, https://shopassociation.org/how-glp-1-meds-are-reshaping-the-us-apparel-market/
- GLP-1 users are changing apparel trends | Retail Dive, https://www.retaildive.com/news/retail-apparel-impact-glp-1-weight-loss-drugs/815662/
- GLP-1 Medications Are Changing the Way Americans Shop, https://www.inc.com/esther-lian/glp-1-medications-ozempic-consumer-behavior-shopping-trends-clothing-apparel/91377622
- How GLP-1 Is Reshaping Apparel Returns – ReturnPro, https://www.returnpro.com/resources/blog/how-glp-1-is-reshaping-apparel-returns
- Fast Fashion Supply Chain Speed: Reducing Lead Times … – Cubic, https://www.gocubic.io/guides/vertical-expertise/fashion-fast-supply-chain
- Lead Time Inventory Planning in Fashion Retail – Stylematrix, https://stylematrix.io/lead-time-inventory-strategies-for-retailers-facing-long-production-cycles/
- (PDF) The Role of Supply Chain Management in Fast Fashion, https://www.researchgate.net/publication/386142689_The_Role_of_Supply_Chain_Management_in_Fast_Fashion_Merchandising
- How the Rise of GLP-1 is Impacting Apparel Retailers, https://clarkstonconsulting.com/insights/glp-1-impact-apparel-retailers/
- Research Reports – Chris Leinberger, https://chrisleinberger.com/research
- Report: Demand Is Rising for Walkable Urban Places – Salud America!, https://salud-america.org/report-demand-is-rising-for-walkable-urban-places/
- NAR Survey Finds Strong Demand for Walkable Communities and, https://www.nar.realtor/news/real-estate-news/nar-survey-finds-strong-demand-for-walkable-communities-and-housing-choice
- Urban Walkability in New York Metro – Up For Growth, https://upforgrowth.org/wp-content/uploads/2022/09/CLIMATE_Urban-Walkability.pdf
- Walkable communities in demand, will lead housing market, https://www.smartgrowthamerica.org/knowledge-hub/news/walkable-communities-in-demand-will-lead-housing-market-recovery-new-report-finds/
- Car Crash Test Dummies Are Getting Fatter Because We Are, Too, https://time.com/3548894/fat-dummies/
- GAO-23-105595, VEHICLE SAFETY, https://www.gao.gov/assets/gao-23-105595.pdf
- Is Individual Weight Loss a Gain for Airlines?, https://www.prevuemeetings.com/news/is-individual-weight-loss-a-gain-for-airlines/
- Jefferies forecasts US airlines will save ~$580M in fuel this … – Reddit, https://www.reddit.com/r/glp1/comments/1qmpuqe/jefferies_forecasts_us_airlines_will_save_580m_in/
- Weight loss drugs could save airlines money on fuel as Americans, https://www.cbsnews.com/news/weight-loss-drugs-glp1s-airlines-fuel-costs/
- The latest winner from weight-loss drugs? Airlines | The Independent, https://www.independent.co.uk/us/travel/airlines-savings-weight-loss-drugs-b2901279.html
- Unexpected GLP-1 Side Effect? Cheaper Airline Tickets, https://www.inc.com/ava-levinson/unexpected-glp-1-side-effect-cheaper-airline-tickets/91289585
- Weight-Loss Drugs Could Have This Surprising Impact on Air Travel, https://www.mensjournal.com/travel/weight-loss-drugs-could-have-this-surprising-impact-on-air-travel
- Bariatric surgeries on the decline as use of GLP-1 drugs rises, https://hsph.harvard.edu/news/bariatric-surgeries-on-the-decline-as-use-of-glp-1-drugs-rises/
- As GLP-1 Use Skyrockets and Bariatric Surgery Slows, Most Obesity, https://asmbs.org/news_releases/as-glp-1-use-skyrockets-and-bariatric-surgery-slows-most-obesity-goes-untreated/
- GLP-1 medications reduced the number of bariatric surgeries, https://www.medicaldevice-network.com/analyst-comment/glp-1-medications-reduced-bariatric-surgeries/
- New Study Finds Metabolic and Bariatric Surgery After GLP-1, https://asmbs.org/news_releases/new-study-finds-metabolic-and-bariatric-surgery-after-glp-1-treatment-significantly-boosts-weight-loss/
- GLP‐1 Receptor Agonists Versus Bariatric Surgery: Effects of Weight, https://pmc.ncbi.nlm.nih.gov/articles/PMC12972600/
- GLP-1 Agonists and Orthopedic Surgery: A Review of Their Impact, https://aoao.org/2025/07/29/glp-1-agonists-and-orthopedic-surgery-a-review-of-their-impact-on-bone-metabolism-wound-healing-and-surgical-outcomes/
- The perioperative use of GLP-1 receptor agonists in patients, https://aoj.amegroups.org/article/view/9786/html
- The Effects of GLP-1 Agonists on Musculoskeletal Health and … – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12325148/
- GLP-1 agonists linked to significantly lower long term risk of knee, https://bmjgroup.com/glp-1-agonists-linked-to-significantly-lower-long-term-risk-of-knee-replacement/
- GLP-1s and joint replacement: 7 numbers every orthopaedic, https://www.beckersspine.com/orthopedic/glp-1s-and-joint-replacement-7-numbers-every-orthopaedic-surgeon-needs-to-know/
- The Impact of Glucagon-Like Peptide-1 Receptor Agonist Use on, https://pubmed.ncbi.nlm.nih.gov/41072556/
- Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists, https://pubmed.ncbi.nlm.nih.gov/41587701/
- Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for, https://pubmed.ncbi.nlm.nih.gov/40289060/
- GLP-1 receptor agonists and sarcopenia: Weight loss at a … – PubMed, https://pubmed.ncbi.nlm.nih.gov/41022269/
- Studies explore: GLP-1 receptor agonist use and its impact on long, https://firstwordpharma.com/story/7123232
- Emerging Role of Myostatin Inhibitors in the Management … – PubMed, https://pubmed.ncbi.nlm.nih.gov/41423189/
- Obesity drugs are among health breakthroughs forecast to boost GDP, https://www.goldmansachs.com/insights/articles/obesity-drugs-are-among-breakthroughs-forecast-GDP
- Economics of Health | NBER, https://www.nber.org/programs-projects/programs-working-groups/economics-health
- NBER WORKING PAPER SERIES THE LABOR MARKET IMPACTS, https://www.nber.org/system/files/working_papers/w35475/w35475.pdf
- When employers cover GLP-1s, workers may take less sick leave, https://www.hr-brew.com/stories/employer-glp-1-coverage-sick-leave
- NBER WORKING PAPER SERIES DO GLP-1 MEDICATIONS PAY, https://www.nber.org/system/files/working_papers/w34678/w34678.pdf
- GLP-1 Therapy and the Reshaping of Socioeconomic Gradients in, https://www.nber.org/system/files/working_papers/w35296/w35296.pdf
- Long-term kidney outcomes of semaglutide in obesity and, https://utsouthwestern.elsevierpure.com/en/publications/long-term-kidney-outcomes-of-semaglutide-in-obesity-and-cardiovas/
- Long-term kidney outcomes of semaglutide in obesity and … – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC11271413/
- GLP-1 Heart and Kidney Outcomes: SELECT and FLOW Explained, https://peptimap.com/blog/glp1-heart-kidney-outcomes/
- FLOW trial demonstrates kidney, cardiovascular benefits of, https://www.adameetingnews.org/flow-trial-demonstrates-kidney-cardiovascular-benefits-of-semaglutide-in-high-risk-patients-with-type-2-diabetes/
- Cardiovascular outcomes with semaglutide by severity of chronic, https://academic.oup.com/eurheartj/article/46/12/1096/7745056
- Cardiovascular, Kidney, and Safety Outcomes With GLP-1 Receptor, https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.071689
- Evaluate Renal Function With Semaglutide Once Weekly – FLOW, https://www.acc.org/latest-in-cardiology/clinical-trials/2024/05/29/17/23/flow
- Impact of Oral Semaglutide on Kidney Outcomes in People … – PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12824789/
- Resmetirom and semaglutide in metabolic dysfunction-associated, https://www.explorationpub.com/Journals/eds/Article/1008132
- Madrigal Announces Positive Topline Results from the Pivotal, https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-announces-positive-topline-results-pivotal-phase-3
- Resmetirom: An Update on Therapy for Metabolic Dysfunction, https://pmc.ncbi.nlm.nih.gov/articles/PMC13005583/
- Real-World Resmetirom Gains in MASH: Naim Alkhouri, MD | AJMC, https://www.ajmc.com/view/real-world-resmetirom-gains-in-mash-naim-alkhouri-md
- Resmetirom Maintains Efficacy for MASH Irrespective of GLP-1 RA, https://www.hcplive.com/view/resmetirom-maintains-efficacy-for-mash-irrespective-glp-1-ra-sglt2i-use
- Analysis: GLP-1s and Mortality Risk – RGA, https://www.rgare.com/knowledge-center/article/analysis–glp-1s-and-mortality-risk
- RGA GLP-1 Study: Weighing the Evidence, https://www.rgare.com/knowledge-center/article/rga-glp-1-study–weighing-the-evidence
- GLP-1s Expected to Reduce US Mortality by 3.5% Over the Next 20, https://investor.rgare.com/news-releases/news-release-details/new-research-rga-glp-1s-expected-reduce-us-mortality-35-over
- Mortality Impact of GLP-1 Drugs | Insurance Thought Leadership, https://www.insurancethoughtleadership.com/life-health/mortality-impact-glp-1-drugs
- Weight Loss Drugs and Insurance: Actuarial Model and Mindset, https://www.soa.org/globalassets/assets/files/resources/research-report/2026/ml295-essay-collection/ml295-weightlossdrugs.pdf
- How underwriters should interpret GLP-1 prescriptions (and what, https://www.rxhistories.com/how-underwriters-should-interpret-glp-1-prescriptions-and-what-they-signal-about-risk/
- GLP-1 therapies and mortality risk: Implications for life insurers, https://www.munichre.com/us-life/en/insights/clinical-knowledge/glp-1-therapies-and-mortality-risk-implications-for-life-insurers.html
- Measuring the Gains from Medical Research, https://press.uchicago.edu/ucp/books/book/chicago/M/bo3643529.html
- The value of longevity: An international analysis – Redalyc, https://www.redalyc.org/journal/1691/169170259002/html/
- Long-term projections of public pension expenditure – OECD, https://www.oecd.org/en/publications/pensions-at-a-glance-2025_e40274c1-en/full-report/long-term-projections-of-public-pension-expenditure_af4ed734.html
- Ageing Populations, Pension Systems and Government Budgets, https://www.oecd.org/en/publications/ageing-populations-pension-systems-and-government-budgets_333823847807.html
- Public expenditure on pensions: Pensions at a Glance 2025 | OECD, https://www.oecd.org/en/publications/2025/11/pensions-at-a-glance-2025_76510fe4/full-report/public-expenditure-on-pensions_ddc9a2dd.html
- Ageing populations, their fiscal implications and policy responses, https://www.oecd.org/en/publications/ageing-populations-their-fiscal-implications-and-policy-responses_6aec03b3-en.html
- Longevity Risk and Private Pensions – OECD, https://www.oecd.org/en/publications/longevity-risk-and-private-pensions_261260613084.html
- Recent pension reforms: Pensions at a Glance 2025 – OECD, https://www.oecd.org/en/publications/2025/11/pensions-at-a-glance-2025_76510fe4/full-report/recent-pension-reforms_146d2687.html
- Old-age pensions: Restoring Public Finances – OECD, https://www.oecd.org/en/publications/2026/05/restoring-public-finances_0c1f7ce5/full-report/old-age-pensions_a94a0115.html
- Public expenditure on pensions: Pensions at a Glance 2025 | OECD, https://www.oecd.org/en/publications/pensions-at-a-glance-2025_e40274c1-en/full-report/public-expenditure-on-pensions_ddc9a2dd.html
- GLP-1s and Fertility: What We Know, https://www.get-carrot.com/blog/glp-1s-and-fertility
- GLP-1 Weight Loss Meds & Fertility | Patient Guide NJ, https://www.damienfertilitypartners.com/blog/glp-1-medications-and-fertility-what-patients-need-to-know/
- GLP-1 Receptor Agonists and Fertility: What Is Known So Far?, https://pubmed.ncbi.nlm.nih.gov/42441883/
- GLP-1 Medications and Fertility: What You Need To Know, https://www.mavenclinic.com/post/glp-1-medications-and-fertility
3. Social Impact Forecast: The Year 2056
Quantifying long-term shifts in traffic safety, domestic violence, sexual assault, and incarceration rates.
Drunk Driving Epidemic Eradication
67% of US alcohol crash fatalities involve drivers with BAC ≥ 0.15 g/dL. By truncating extreme binge drinking, GLP-1 RAs preemptively prevent high-BAC vehicle operations, saving ~10,000+ lives annually.
Domestic & Sexual Violence Decline
Alcohol is present in 65% of spousal violence cases and 90% of campus acquaintance rapes. Eliminating severe intoxication disinhibition slashes opportunistic violent assaults.
Prison Deflation
85% of current prison inmates have an active SUD or committed drug-involved crimes. Prophylactic addiction control deflates correctional caseloads.
Projected Annual Incident Trends (2026 – 2056)
Normalized index (2026 baseline = 100). Demonstrates S-curve adoption impact.